Ceftizoxime-induced immune hemolytic anemia associated with multi-organ failure.
10.12701/yujm.2017.34.1.123
- Author:
Jin Young HUH
1
;
Ari AHN
;
Hyungsuk KIM
;
Seog Woon KWON
;
Sujong AN
;
Jae Yong LEE
;
Byoung Soo KWON
;
Eun Hye OH
;
Do Hyun PARK
;
Jin Won HUH
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jwhuh@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
Ceftizoxime;
Hemolytic anemia;
Plasmapheresis
- MeSH:
Acute Kidney Injury;
Aged;
Anemia, Hemolytic*;
Antigen-Antibody Complex;
Ceftizoxime;
Cephalosporins;
Diagnosis;
Hematologic Tests;
Hemolysis;
Humans;
Liver Failure;
Palliative Care;
Photochemotherapy;
Plasmapheresis;
Renal Replacement Therapy
- From:Yeungnam University Journal of Medicine
2017;34(1):123-127
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Drug-induced immune hemolytic anemia (DIIHA) is a rare side effect of drugs. DIIHA may cause a systemic inflammatory response that results in acute multi-organ failure and death. Ceftizoxime belongs to the class of third generation cephalosporins, which are the most common drugs associated with DIIHA. Herein, we present a case of a 66-year-old man who developed fatal DIIHA after receiving a second dose of ceftizoxime. He was admitted to receive photodynamic therapy. He had a history of a single parenteral dose of ceftizoxime 3 months prior to admission. On the day of the procedure — shortly after the infusion of ceftizoxime — the patient's mental status was altered. The blood test results revealed hemolysis. Oliguric acute kidney injury developed, and continuous renal replacement therapy had to be applied. On the suspicion of DIIHA, the patient underwent plasmapheresis. Diagnosis was confirmed by a detection of drug-dependent antibody with immune complex formation. Although his hemolysis improved, his liver failure did not improve. He was eventually discharged to palliative care, and subsequently died.
